A Phase 3 interventional study of Revelise (GENERIUM, Russia) and Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany) in Myocardial Infarction (MI), sponsored by AO GENERIUM. Completed at 22 sites in Russia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-28.
Sponsored by AO GENERIUM · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myocardial Infarction with a site in Russia — 7 open to participants now, 8 under way, 1 of them phase 3. Myocardial Infarction · Russia.
Among the 19 studies in Myocardial Infarction with a site in Russia, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 3, and was the 15th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →7 of the 19 studies in Myocardial Infarction with a site in Russia are open now. Recruiting first, the newest first:
ITMO University · Sites in Russia
Ages 18+
Novartis Pharmaceuticals · Sites in Russia
Ages 18–100
Efferon JSC · Sites in Russia
Ages 18–80
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Ages 18–90
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Sites in Russia
Ages 18+
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1984; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 161 across the 12 interventional studies, 504 across the 7 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 19 have an industry lead sponsor. The 10 most frequent:
AO GENERIUM is the lead sponsor of 31 studies on the registry; 3 are open to participants now.
AO GENERIUM has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Infarction with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04347200National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-1 | 2026-12-31 |
| NCT07230249ITMO UniversityTelegram Messenger Support for Smoking Cessation After Heart Attack | 2027-04-27 |
| NCT06955936Efferon JSCEfferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction | 2027-04-29 |
| NCT07142265Novartis PharmaceuticalsEvaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myocardial Infarction with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany) in patients with acute myocardial infarction (MI) with ST-segment elevation on the electrocardiogram (ECG). The thrombolisis was performed within the period of up to 6 hours and from 6 to 12 hours from the MI symptoms onset.
Revelise®, lyophilizate for solution for infusion, 50 mg, is the proposed biosimilar recombinant human tissue plasminogen activator developed by GENERIUM JSC (Russia).
All the patients with acute myocardial infurction, enrolled into the study, have been randomised to receive either biosimilar product or a reference produc. The stratification factor was the time from the MI symptoms onset: 1) within the 6 hours and 2) from 6 to 12 hours. Each patient was then followed-up for 3 months, including up to 14 days in an inpatient facility. Coronary angiography was to be performed within the first 24 hours after the administration of the study products, but not earlier than 3 hours after beginning of infusion in case of confirmed thrombolysis (onset of myocardial reperfusion) and immediately - in the absence of reperfusion according to ECG data (ST-segment reduction by less than 50% afterthe infusion start). The patients' condition will be assessed at the scheduled visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Significant bleeding at present or during the previous 6 months, hemorrhagic diathesis.
4. Congenital-hereditary hemorrhagic coagulopathy (hemophilia, etc.) in medical history 5. Concomitant administration of oral anticoagulants, for example, warfarin ( > 1.3).
6. Surgery of the brain or spinal cord, neoplasms of the brain or spinal cord in past medical history, traumatic brain injury during the last 3 months.
7. Intracranial (including subarachnoid) hemorrhage currently or in past medical history.
8. Hemorrhagic stroke or stroke of unknown etiology in the anamnesis, suspected hemorrhagic stroke.
9. Ischemic stroke or during the last 6 months. 10. Severe (systolic blood pressure higher than 185 mmHg or diastolic blood pressure higher than 110 mmHg) uncontrolled hypertension.
11. Extensive surgery or significant trauma during the previous 3 weeks (including any injury combined with this acute myocardial infarction).
12. Long-term or traumatic cardiopulmonary resuscitation (>2 min), delivery during the previous 10 days; recently performed puncture of an incompressible blood vessel (for example, subclavian or jugular vein).
13. Bacterial endocarditis, pericarditis. 14. Known arterial aneurysms, defects in arteries or veins' development, suspected aortic dissection.
15. Confirmed gastric ulcer or duodenal ulcer during the last 3 months. 16. Known severe liver diseases, including liver failure, cirrhosis, portal hypertension (including esophageal varicose veins dilatation), active hepatitis.
17. Acute pancreatitis. 18. Known neoplasm with an increased risk of bleeding. 19. to the components of the product, allergic reactions to gentamicin in past medical history.
20. Pregnancy or lactation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
аlteplase
Biological: Revelise (GENERIUM, Russia)
аlteplase
Biological: Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg. \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes. 2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg. * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg.
Drug page: Tissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
1. 90-minute accelerated dosing regimen for patients who can start treatment within 6 hours after the onset of symptoms of acute myocardial infarction (AMI): Initial bolus injection: 15 mg intraveniously (IV) followed by an infusion of 50 mg over 30 minutes and then a subsequent infusion of 35 mg over 60 minutes to reach a maximum total dose of 100 mg. \- For patients less than 65 kg: Initial bolus injection: 15 mg IV - 0.75 mg/kg (maximum 50 mg) over 30 minutes followed by an additional infusion of 0.5 mg/kg (maximum 35 mg) over 60 minutes. 2. 3-hour dosing regimen for patients who can start treatment between 6 and 12 hours after symptom onset of AMI: Initial bolus injection: 10 mg IV followed by an infusion of 50 mg over 60 minutes and then a subsequent infusion of 40 mg over 120 minutes to achieve a maximum total dose of 100 mg. * For patients less than 65 kg: The cumulative dose should not exceed 1.5 mg/kg.
Myocardial reperfusion rate confirmed by the coronary angiography (CAG)
Myocardial reperfusion confirmed by the CAG: coronary blood flow TIMI 3 or 2 degrees are considered to be myocardial reperfusion. Grade 3 - normal coronary perfusion: antegrade blood flow and contrast washout distal to the site of obstruction do not differ from those in an unaffected vessel; grade 2 - incomplete coronary perfusion: complete contrasting of the coronary artery distal to the site of obstruction, however, there is a delay in filling of the distal bed or slowdown in contrast washout).
Time frame: In 3 hours after the beginning of IV thrombolysis in case of ECG data of successful reperfusion and immediately - if there is no effect of thrombolysis based on ECG data.
Frequency of percutaneous coronary intervention (PCI)
Frequency of performing PCI after the intravenous thrombolysis results.
Time frame: During the first day after the intravenous thrombolysis, but not earlier than 3 hours after the start of the infusion in case of coronary reperfusion and immediately in case of nocoronary thrombolysis based on ECG data
Cardiovascular mortality
Cardiovascular mortality in the period up to 30 days after acute myocardial infarction
Time frame: Up to 30 days after acute myocardial infarction
Myocardial reperfusion rate according to ECG data.
Myocardial reperfusion rate according to ECG data - by ST-segment resolution (reduction) by 30%, 50%, 70% or more than 90 minutes after the beginning of the product administration in patients with acute myocardial infarction for up to 6 hours and by ST-segment resolution (reduction) by 50% or more than 180 minutes after the beginning of the product administration in patients with acute myocardial infarction during the period from 6 to 12 hours from the disease onset. (Resolution of ST segment elevation is calculated as follows: the amount (by leads) of ST segment elevation before therapy (at point J) minus the amount of ST segment elevation after therapy (90 or 180 minutes after the beginning of the product administration) divided by the amount of ST segment elevation before therapy and expressed as a percentage.)
Time frame: 90 or 180 minutes after the beginning of the IV thrombolysis.
Overall mortality
Any cause mortality after acute myocardial infarction
Time frame: Up to 90 days
Incidence of post-infarction complications
Incidence of post-infarction complications (true cardiogenic shock, clinical signs of congestive heart failure, acute left ventricular aneurysm, cardiac rupture, early post-infarction angina, recurrent myocardial infarction, brain infarction) during the first 30 days, except the rhythm disturbances
Time frame: 30 days
Incidence of the combined cardiovascular events
Incidence of the combined cardiovascular events "death from cardiovascular diseases + recurrence of myocardial infarction + stroke" and "death from cardiovascular diseases + recurrence of myocardial infarction + stroke + heart failure" within 30 and 90 days after the acute myocardial infarction
Time frame: Within 30 and 90 days
Troponin changes
Troponin concentration changes during the first 14 days after acute myocardial infarction
Time frame: 14 days
Fibrinogen concentration
Concentration of fibrinogen in plazma sample
Time frame: Days 1, 2 and 3
D-dimer concentration
Concentration of the D-dimer in plazma sample
Time frame: Days 1, 2 and 3
Plan to share: No
Ran from May 2014 to primary completion in Nov 2017, 41 months.
Of 58 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 41 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.